
2007
 |
|
|
|
 |
 |
Investigator |
 |
Institution |
 |
Project |
 |
|
Ken Aldape, MD |
|
M.D. Anderson Cancer Center, TX |
|
Multigene predictors of outcome in glioblastoma. |
 |
|
Panos Anastasiadis, PhD |
|
Mayo Clinic, FL |
|
Cadherins and catenins as biomarkers of pediatric and adult glioma aggressiveness. |
 |
|
Markus Bredel, MD, PhD |
|
Northwestern University, IL |
|
Predicting the therapy response of high-grade gliomas based on a network of endogenous modulators of NFkB. |
 |
|
Joseph Costello, PhD.* |
|
University of California, San Francisco, CA |
|
Evolution of a hypomethylated and hyperproliferative phenotype in GBM and its reversal by a high methyl-donor diet. |
 |
|
Alan D'Andrea, MD. |
|
Dana-Farber Cancer Institute, MA |
|
Inhibition of ATM and CHK2 as treatment for glioblastoma multiforme. |
 |
|
Xing Fan, MD, PhD. |
|
Johns Hopkins University, MD |
|
Depleting cancer stem cells by notch pathway blockade in glioblastomas. |
 |
|
Qihong Huang, MD, PhD. |
|
The Wistar Institute, PA |
|
Development of microRNA inhibitors for the treatment of glioblastomas. |
 |
|
Gary Landreth, PhD. |
|
Case Western Reserve University, OH |
|
Efficacy of PPARg agonists in treatment of glioma. |
 |
|
Meng Law, MD. |
|
Mount Sinai Medical Center, NY |
|
Standardization of perfusion MR imaging and predicting clinical outcome in patients with gliomas using perfusion MR metrics in a multi-institutional setting. |
 |
|
Duane Mitchell, MD, PhD. |
|
Duke University, NC |
|
RNA loaded dendritic cell vaccines targeting brain tumor stem cells during hematopoietic recovery from temozolomide-induced lymphopenia. |
 |
|
Inder Verma, PhD. |
|
The Salk Institute, CA |
|
Novel therapies for glioblastomas. |
 |
|
Al Yung, MD. |
|
MD Anderson Cancer Center, TX |
|
Identification of compensatory molecular pathways using functional genomic and synthetic lethality screening in glioblastoma treated with PI3K inhibitors. |
 |
|
 |
|
|
|
 |
* Jointly awarded by Accelerate Brain Cancer Cure and the Tug McGraw Foundation
|
|